New York, January 7, 2026, 12:25 (EST) — Regular session
- Shares of Adaptive Biotechnologies were up about 6.5% in midday trade.
- Biotech ETFs were also higher, beating the broader market.
- A Form 4 showed an executive sold shares under a 10b5-1 plan.
Shares of Adaptive Biotechnologies rose 6.5% to $17.15 on Wednesday, after trading between $16.24 and $17.33, giving the company a market value of about $2.0 billion. The stock has traded between $4.32 and $21.89 over the past 52 weeks.
The move matters now because investors have been bidding up riskier biotech names again, and ADPT tends to swing with that tone. The SPDR S&P Biotech ETF and the iShares Nasdaq Biotechnology ETF were each up about 2.5% in midday trade.
The broader market was also higher, but not by as much. The Nasdaq 100 tracker was up about 0.7% and the S&P 500 tracker gained about 0.3%.
A securities filing showed Chief People Officer Francis Lo sold 3,125 shares on Jan. 2 at a weighted average price of $16.08, after exercising options for the same number of shares at $3.99. The transactions were carried out under a Rule 10b5-1 trading plan Lo adopted on Sept. 15, 2025, and the Form 4 was filed on Jan. 6.
Adaptive Biotechnologies sells immune-based genetic tests used in oncology and other disease areas, including tools that read immune receptor sequences to help spot hard-to-detect disease. The company is not consistently profitable, which can leave the stock more sensitive to shifts in growth-stock appetite.
Investors are also looking ahead to management’s scheduled appearance at the J.P. Morgan Healthcare Conference on Jan. 12, when the company is due to take part in a fireside chat at 4:30 p.m. Pacific time, the company has said.
Sales under 10b5-1 plans are set up in advance, so they are often treated as routine. Still, the filing puts a line under insider selling activity at a time when the shares are trying to push higher.
But the rally can cut the other way. If the broader biotech bid cools, or if next week’s conference brings little new on growth, cash use or partnerships, ADPT can give back gains quickly.
Related articles: Biotechnology
